Twelve Rules for Vetting a Stem Cell Practice in Korea (2026)

One arrives in Cheongdam expecting a brochure conversation, and the better Korean regenerative-medicine practices — and this matters — do not run one. The consult rooms are paced more slowly than the appointment slot suggests; the protocol vocabulary is calibrated more carefully than the marketing materials imply; the rules worth carrying in are mostly the ones the practice will not hand a visitor on a printed card. What follows is an editorial reading of twelve rules — regulatory, clinical, and consult-room disciplines — for a patient considering a Korean cellular protocol. The list is categorical, not ranked. 慢慢諗清楚先決定.

Methodology — how the twelve rules were drawn

The rules below were drawn from a triangulation of three sources, and the editorial register is calibrated accordingly. The first source is the published Korean regulatory framework governing cellular therapy — the Ministry of Food and Drug Safety's cellular-therapy register, the Korea Health Industry Development Institute's foreign-patient guidance, and the Pharmaceutical Affairs Act provisions that govern cellular-product manufacturing and clinical use. The second source is the consult-room reading of the longer-tenured Cheongdam, Apgujeong, and Sinsa-adjacent practices — drawn from clinician conversations, patient-facing protocol documents, and the markers the conservative practices themselves treat as central to their clinical disposition. The third source is a comparative reading against regenerative-medicine standards in adjacent markets — Japan's PMDA cellular-therapy framework, Taiwan's TFDA register, Singapore's HSA cellular-product oversight, and the United States' FDA Section 351/361 product distinction in the relevant clinical registers. No clinic is named in what follows, and no clinic is ranked. Korean medical-tourism law (Article 56(4) of the Medical Service Act) treats direct ranking and named comparison of healthcare providers in foreign-patient contexts as a regulated matter, and the editorial register here is calibrated to the legal framework. What the list offers is a categorical rule-set — the disciplines a patient should carry into a Korean cellular-therapy consult — rather than a directory of practices. The rules are intended as a checklist for the patient's own consult conversations; the slower consults will read the rules as familiar, and the discipline of the practice will be legible in the consult conversation rather than in the brochure.

Rule #1 — Verify MFDS registration before the first consult fee is paid

The first rule, and the non-negotiable one in the conservative Korean reading, is to verify the Ministry of Food and Drug Safety's registration status of the cellular product the practice administers — and to do the verification before any consult fee is paid. The MFDS maintains a publicly accessible cellular-therapy register; the better practices will share their registration reference at the inquiry stage rather than treating it as a consult-room disclosure. A practice that softens the registration question, that points to overseas precedent without articulating the domestic register, or that treats the cellular product as research-grade without disclosing the research-protocol framework it sits within is, in the cleaner reading, signalling something a careful patient should not negotiate. The verification is not a procedural formality; it is the first reading of the practice's regulatory disposition. The Korean [Ministry of Food and Drug Safety register](https://www.mfds.go.kr/eng/index.do) is the source the conservative practices reference routinely, and the inquiry-stage transparency is itself a marker.

What to look for: - Registration reference shared at the inquiry stage rather than at the consult - Indication scope on the registration matching the indication being treated - Clear disclosure of the cellular product's source, processing arc, and lot register - Willingness to walk a patient through the register's public listing directly

Specialty: Regulatory framework competence. Pricing tier: $$ (regulatory infrastructure adds floor cost). Location range: The longer-tenured Cheongdam and Apgujeong corridors host most of the practices that have absorbed the regulatory framework most cleanly; some Sinsa-side practices share that disposition, and the rule reads more cleanly in institutionally older settings.

Rule #2 — Read the consent document before the consult, not in the consult

The second rule reads in the timing of the informed-consent document. A serious cellular-therapy consent document is, on a careful reading, twelve to twenty pages of patient-facing prose — mechanism, indication, evidence base, adverse-event register, contraindication framework, alternative interventions, cost, and the cellular product's source and processing arc. A document of that substance cannot be read in the consult room under the procedural pressure of an appointment slot. The conservative Korean practices will deliver the consent document twenty-four to seventy-two hours in advance of the consult, will invite the patient to read it in their own time, and will treat the consult as the conversation that follows the patient's first reading. A practice that hands the consent document over the consult-room desk and asks for a signature in the same hour is, in the cleaner Gangnam reading, compressing the discipline that the protocol requires. The rule extends past the document. Patients should expect the practice to welcome questions on the consent's substance — clarifications on the cellular product's processing arc, on the adverse-event register's scope, on the alternative interventions disclosed — and to read the conversation's depth as part of the consult's discipline. A 2022 Lancet review of consent practices in regenerative medicine framed advance delivery as a structural marker rather than a procedural courtesy; the framing reads, in my view, as the correct one.

What to look for: - Consent document delivered twenty-four to seventy-two hours before the consult - Patient-readable language without procedural-permission compression - Welcome of consent-substance questions before any signature is requested - Alternative interventions disclosed within the consent's body, not as an addendum

Specialty: Consent discipline. Pricing tier: $$ (the discipline is structural, not price-tier-driven). Location range: The discipline is most consistent in the practices with longer foreign-patient tenure; the Cheongdam and Apgujeong corridor and select Sinsa-adjacent practices sustain it most reliably.

Rule #3 — Confirm the lead clinician's specialty board affiliation

The third rule reads in the lead clinician's specialty board affiliation — and specifically in whether the affiliation matches the indication register under which the cellular protocol is being proposed. A clinician trained in orthopaedic surgery whose practice administers cellular protocols for joint indications reads consistently with the indication; a clinician whose specialty board is in a different register entirely, and whose cellular work has been added to the practice without an articulated training arc, reads less cleanly. The conservative Cheongdam practices treat the credential disclosure as routine; the editorial pages of the longer-tenured practices articulate the lead clinician's medical training, board affiliation, and — if the cellular work sits within a specific indication register — the relevant subspecialty training arc. Patients should expect to read, on the practice's editorial pages or at the consult, the lead clinician's training arc and to weigh the credential register above the lobby's appointments. The rule extends past the lead clinician. The practice's nursing staff, the cellular-product processing team, and the laboratory's quality-management framework are all part of the protocol's institutional depth, and the older practices will speak to the staff infrastructure directly when asked.

What to look for: - Specialty board affiliation matching the indication register being treated - Training arc in regenerative medicine articulated in the practice's editorial materials - Nursing and processing staff credentials referenced in protocol documents - Continuing-education and protocol-update framework disclosed routinely

Specialty: Clinician training depth. Pricing tier: $$$ (senior clinicians command consult-fee premiums). Location range: The older Cheongdam and Apgujeong corridors host most of the longest-tenured regenerative-medicine clinicians; some Sinsa-side practices share that depth, and a careful reading should weight credential depth above the address.

Rule #4 — Insist on imaging and laboratory work-up before the protocol is named

The fourth rule reads in the work-up the practice requires before the cellular protocol is named. The conservative Korean practices treat the work-up as the protocol's first step rather than as procedural overhead — laboratory panels for the systemic-medicine context, imaging appropriate to the indication (ultrasound, MRI, or the relevant cross-sectional modality), a thorough medication and supplement review with a defined wash-out window, and an indication-specific functional assessment where the literature supports it. A practice that names the protocol before the work-up has been read, that compresses the work-up into the same visit as the procedure, or that treats the imaging as optional is, in the cleaner reading, working under thinner discipline than the indication requires. The work-up serves three protocol purposes: it confirms the indication; it surfaces the contraindications that the cellular protocol cannot accommodate; and it establishes the baseline against which the protocol's response will be read across the surveillance arc. Patients arriving from markets where same-day procedure has become the default should expect, in the conservative Korean register, the multi-visit arc to be the standard. The Mayo Clinic's [overview of regenerative medicine work-up frameworks](https://www.mayoclinic.org/tests-procedures/regenerative-medicine/about/pac-20384859) offers a usefully measured patient-facing reading of why the work-up matters.

What to look for: - Imaging appropriate to indication required before the protocol is scheduled - Laboratory panel including the systemic-medicine and contraindication screen - Medication and supplement review with a defined wash-out window - Multi-visit consult arc rather than same-day procedure compression

Specialty: Pre-treatment rigour. Pricing tier: $$ (the work-up is itself billable and the discipline shows in the bill's line items). Location range: The older Cheongdam orthopaedic-and-regenerative practices and the longer-tenured aesthetic-medicine practices both sustain the work-up framework; the newer corridor-edge practices read as more variable on this rule.

Rule #5 — Demand cellular product traceability documentation

The fifth rule is one most patients do not know to ask about and one the better practices volunteer. Cellular therapy depends, at its mechanism, on the cellular product itself — its source, its processing arc, its quality-control register, and its lot identification. The conservative Korean practices maintain a documented traceability framework — patient-facing in summary form, audit-grade in the laboratory's records — that lets a patient or a downstream clinician identify exactly which cellular preparation was administered, under what processing protocol, on which date, with which quality-control register attached. The practices that maintain the documentation will share its summary form at the consult; the practices that do not are, in the conservative reading, working under thinner discipline than a careful patient should accept. The rule is not procedural formality. Traceability connects the patient's clinical record to the adverse-event register; it preserves the clinical-care continuity for any downstream clinician the patient consults; and it positions the cellular protocol within the regulatory register it was administered under. A 2023 review on regenerative-medicine quality frameworks in the Cell Transplantation literature framed traceability as 'the floor of any defensible cellular protocol,' and the framing reads, in my view, as the correct one. Patients should expect to receive the lot identification and processing-protocol documentation as part of the post-procedure record.

What to look for: - Lot identification documentation provided in the patient-facing record - Cellular source, processing protocol, and quality-control register articulated - Audit-grade laboratory records maintained beyond the patient summary - Cold-chain or processing-chain documentation accompanying the cellular product

Specialty: Quality-management infrastructure. Pricing tier: $$$ (laboratory infrastructure costs read into pricing). Location range: Cheongdam clinics with their own on-site cellular-processing wings tend to read most consistently on this rule; the practices that outsource processing should be asked about the upstream laboratory's quality framework directly.

Rule #6 — Require an itemised, line-by-line quotation

The sixth rule reads in the quotation the practice provides before any commitment is asked of the patient. A serious quotation itemises the consult fee, the work-up costs, the cellular product cost, the procedure fee, the post-procedure surveillance arc, and the contingency framework for any adjunct intervention the protocol might require. A quotation compressed into a single 'package price' without itemisation is, in the conservative Korean reading, a marker that the practice has read its own pricing incompletely or — less charitably — has absorbed pricing practice from registers a careful patient should walk past. The cleaner Gangnam practices treat the itemised quotation as routine; the discipline reads as quietly luxurious in the same way the consult rooms read. Patients arriving from markets where 'package pricing' has become the default should expect, in the conservative Korean register, the line-item disclosure to be the standard. The cost question extends past the headline number. Patients should expect to read, on the quotation, the foreign-patient surcharge framework if any applies, the medical-tourism agency referral structure if any applies, the payment-method discount or surcharge framework, and the cancellation and refund framework. The disclosure register is the rule; the headline number is not. A medical-tourism agency that compresses the practice's itemisation into a single 'package' figure is, by its own register, signalling the same thinning the rule is meant to surface.

What to look for: - Line-item quotation across consult, work-up, product, procedure, surveillance - Foreign-patient surcharge structure disclosed if applicable - Agency referral structure disclosed if applicable - Cancellation, refund, and contingency frameworks articulated

Specialty: Cost transparency. Pricing tier: $$ (the discipline is structural, not price-tier-driven). Location range: The discipline is more reliably present in the longer-tenured Cheongdam and Apgujeong practices; the medical-tourism agency channel reads as more variable, and a careful patient should ask the agency the same itemisation question they ask the practice.

Rule #7 — Ask about the practice's adverse-event reporting record

The seventh rule reads in how a practice handles the rare cases where a cellular protocol does not perform as expected. The conservative Korean practices maintain a documented adverse-event reporting framework that connects the patient's record to the Ministry of Food and Drug Safety's pharmacovigilance register, with a defined post-procedure surveillance arc — typically three days, two weeks, six weeks, and three months in the conservative practice's protocol — and an explicit framework for escalating any adverse-event signal beyond the practice's internal review. A practice that treats the post-procedure visit as routine reassurance rather than as a structured surveillance step is, in the cleaner reading, working under thinner discipline than the protocol requires. The rule is not theoretical. Patients should ask, at the consult, what the practice's adverse-event reporting arc looks like, whether the practice contributes to the MFDS pharmacovigilance register, and how the practice has handled past adverse-event signals; the directness of the answer is itself part of the rule. A practice that softens the adverse-event question, that frames its complication record as 'never had an issue,' or that treats the question as adversarial is signalling something the cleaner consult rooms would treat as a marker. The pharmacovigilance framework matters for the patient's individual clinical record and for the regenerative-medicine register's broader signal — the practices that contribute to the registry's quality are the ones that have absorbed the regulatory framework most fully.

What to look for: - Structured post-procedure surveillance arc with defined check-in points - Documented adverse-event reporting connection to the MFDS register - Internal protocol review framework with a documented escalation path - Willingness to discuss the practice's prior adverse-event experience directly

Specialty: Pharmacovigilance discipline. Pricing tier: $$$ (the surveillance arc is calibrated rather than minimal). Location range: The discipline is most consistent in the older Cheongdam and Apgujeong practices that have processed substantial cellular-therapy patient volume across multiple years; newer practices may articulate the framework but lack the institutional patient-volume to have stress-tested it.

Rule #8 — Confirm the foreign-patient registration is current and substantive

The eighth rule reads in the practice's foreign-patient infrastructure — the registration with the Korea Health Industry Development Institute's foreign-patient framework, the language support across the consult and surveillance arc, the medical translator's clinical literacy, and the support across the visa, accommodation, and post-procedure logistics. A practice with substantive foreign-patient tenure will have built infrastructure beyond a translator's bilingual register — a clinical-literacy framework that lets the patient's translator read the consent document accurately, a post-procedure surveillance protocol that accommodates the patient's home-country clinical record, and a downstream-clinician handoff framework for the patient's home-country care continuity. A practice that has the registration without the institutional depth — the translator who is bilingual but not clinically literate, the surveillance protocol that does not accommodate the patient's home-country follow-up, the consent document available only in Korean — is working under a thinner framework than substantive cross-border care requires. The rule is one of the cleaner reads in the foreign-patient register. The KHIDI foreign-patient portal lets a patient verify the registration status directly; the institutional depth, however, reads only at the consult. Patients should ask, at the consult, what the practice's foreign-patient registration status is, what the language-support arc looks like across the work-up and surveillance, and how the practice handles the downstream-clinician handoff after the patient returns home; the answers' substance is the rule.

What to look for: - KHIDI foreign-patient registration current and verifiable - Clinical-literacy translator framework, not only conversational bilingual register - Patient-facing materials available in the patient's primary working language - Downstream-clinician handoff framework articulated for home-country continuity

Specialty: Foreign-patient infrastructure. Pricing tier: $$ (the infrastructure is amortised across the foreign-patient flow). Location range: The Cheongdam, Apgujeong, and select Sinsa-adjacent practices that have built foreign-patient registries across the past decade read most consistently; newer practices may have the registration without the institutional depth.

Rule #9 — Ensure the consult is indication-driven, not protocol-led

The ninth rule is one of the cleanest disciplines a regenerative-medicine practice can demonstrate, and it reads in the consult conversation rather than in the brochure. An indication-driven consult begins with the patient's complaint, works through the imaging and laboratory work-up, articulates the indication and stage of presentation, and only then arrives at the protocol that fits the indication. A protocol-led consult begins with the protocol the practice favours, fits the patient's complaint into the protocol's indication frame, and treats the indication conversation as a procedural step rather than as the consult's centre. Patients should expect the older Korean practices to ask a series of clarifying questions before any protocol is named — about the symptoms' onset, the prior interventions tried, the imaging available, the systemic-medicine context — and to defer the protocol conversation until the indication has been read. A consult that names the protocol in the first ten minutes, that frames the cellular work as the answer before the indication conversation has happened, or that treats the patient's preference as the consult's centre is, in the conservative reading, the consult to step back from. The rule reads more cleanly the longer the consult runs. The slower consults — forty-five to sixty minutes for an initial indication conversation, with the work-up and protocol named at returning visits — are the consults the conservative Korean practices sustain.

What to look for: - Imaging and laboratory work-up requested before any protocol is named - Willingness to redirect to alternative interventions (PRP, conservative protocols, surgery) - Systemic-medicine and medication review as part of the consult arc - Multi-visit consult cadence rather than single-hour protocol-and-procedure compression

Specialty: Indication discipline. Pricing tier: $$ (consult time is calibrated, but not premium-priced). Location range: The discipline is more consistent in the longer-tenured Cheongdam and Apgujeong practices than in the newer Yeoksam-side or Sinsa-side practices that have entered the corridor in the past decade.

Rule #10 — Watch for the willingness to redirect or refuse

The tenth rule is the quietest and, on a careful reading, perhaps the most diagnostic. The better Korean regenerative-medicine practices share an editorial disposition — a willingness to say 'this protocol is not the right fit for your indication,' or 'the cellular conversation is not the first conversation for the stage you are presenting at,' or 'the indication is more cleanly addressed by a conservative-protocol arc, and we would prefer to refer you to a colleague for that.' The redirection is the rule. A practice that proposes the cellular protocol regardless of the indication, the stage, or the work-up's findings is, in the conservative Cheongdam reading, signalling something a careful patient should attend to. A practice that redirects — even at the cost of the consult fee, even at the cost of the procedure that would have followed — is, in the older clinical disposition, working at the discipline that the protocol requires. The rule reads at the moment the consult turns from confirming the patient's preference to confronting the patient's indication; the cleaner consults handle the turn calmly, and a careful patient should read the calmness as the discipline. 唔啱條件就要轉介, as the Cantonese phrasing has it — if the indication does not fit, the referral is part of the consult. The editorial reading is consistent across the older Korean medical-aesthetic and regenerative-medicine literature: the practices that have built durable international reputations have done so partly on the discipline of indication, and the discipline of indication is, at its core, the willingness to redirect when the indication does not fit.

What to look for: - Documented willingness to redirect to alternative interventions or colleagues - Consult conversation that confronts the indication rather than confirming the preference - Referral framework articulated routinely in the consent and consult conversation - Calmness in the redirection — the discipline of refusing without performing the refusal

Specialty: Editorial discipline. Pricing tier: $$$ (the disposition is the discipline; the discipline is the practice's reputational floor). Location range: The longest-tenured Cheongdam and Apgujeong practices, and select Sinsa-adjacent practices with multi-decade institutional histories, sustain the disposition most consistently.

Rule #11 — Independently verify any clinical claim

The eleventh rule reads in how the practice handles the evidence base behind its protocols. A serious cellular-therapy practice will articulate the published evidence base for the indication being treated — the relevant clinical-trial literature, the systematic reviews, the registry data where it exists — and will distinguish, calmly and without softening, the indications where the evidence base is robust from the indications where the cellular work remains exploratory. A practice that frames the cellular protocol as universally evidence-supported, that cites generic 'studies' without naming the indication-specific literature, or that softens the evidence-base distinction between robust and exploratory indications is signalling something a careful patient should weigh. The rule extends to independent verification. Patients should expect the practice to share — at the consult or in the consent document — the indication-specific literature references the protocol relies on, and should treat the references as a starting point for the patient's own reading rather than as the conversation's endpoint. Public databases such as PubMed, the Cochrane Library, and the relevant specialist registries let a patient verify the literature directly. A practice that welcomes the verification reads as one disposition; a practice that treats the verification as adversarial reads as another. The rule is not academic. The cellular-therapy literature is genuinely heterogeneous across indications — some indications sit on a robust evidence base, others remain exploratory — and a patient who internalises the heterogeneity is in the consult conversation the conservative Korean practices most welcome.

What to look for: - Indication-specific literature references articulated in the consent document - Calm distinction between robust-evidence and exploratory-evidence indications - Welcome of independent verification of the cited literature - Clear communication when an indication remains within an exploratory evidence base

Specialty: Evidence-base literacy. Pricing tier: $$ (the discipline is structural, not price-tier-driven). Location range: The longer-tenured Cheongdam and Apgujeong practices, and the Sinsa-adjacent practices with academic-medicine affiliations, read most consistently on this rule.

Rule #12 — Trust the consult-room atmosphere as much as the protocol

The twelfth rule is the most editorial and the one a careful patient should weight only after the eleven structural rules have been read. The atmosphere of a Korean regenerative-medicine consult — the lobby's pacing, the consult room's quiet, the clinician's cadence, the staff's calmness — is, on a careful reading, a reliable signal of the practice's clinical disposition. The conservative Cheongdam practices have lobbies that read more like Mandarin Oriental's lounge than a brochure-driven sales space; the consult rooms are paced more slowly than the schedule implies; the clinician's cadence is unrushed; the staff handle the patient's logistics with the discreet attention that the longer-tenured practices treat as part of the protocol. A practice whose lobby reads loud, whose consult rooms feel rushed, or whose staff cadence reads as transactional is signalling something a careful patient should weigh against the structural rules. The rule has a careful boundary. Atmosphere is not a substitute for the eleven structural rules; a practice can read luxuriously without sustaining the regulatory and clinical disciplines. The rule is, instead, a tiebreaker — the read that matters when two practices read comparably across the structural rules and the patient is choosing between them. The slower consult, the quieter lobby, the unrushed cadence read consistently in the conservative Korean clinical disposition; the faster consult, the louder lobby, the rushed cadence read consistently with thinner discipline. The reading is editorial. It is also, in my reading across the older Gangnam corridors, useful.

What to look for: - Lobby pacing that reads as hospitality-grade rather than transactional - Consult-room cadence that runs slower than the schedule's appointment slot suggests - Staff calmness in handling logistics, language, and post-procedure coordination - Atmosphere as a tiebreaker after the eleven structural rules have been satisfied

Specialty: Editorial reading. Pricing tier: $$$ (atmosphere is the most expensive layer to sustain). Location range: The Cheongdam and Apgujeong corridors, and select Sinsa-adjacent practices with multi-decade institutional histories, sustain the atmosphere most consistently; the rule reads least cleanly in the corridor's newer entrants.

Comparison table — the twelve rules, side by side

The categorical comparison below summarises the twelve rules across specialty, pricing-tier read, and the broader location range where the rule is most consistently present. The table is offered as a categorical framework rather than as a ranking; no practice is named, and no practice is positioned against another. Patients should treat the table as a checklist for their consult conversations rather than as a directory.

Editorial note — how to carry the twelve rules into the consult

The twelve rules are a working framework for the patient's consult conversations rather than a directory of practices, and the distinction is the editorial spine of the piece. No practice will read uniformly well across all twelve rules; the conservative reading is to weight rules one through five — regulatory verification, advance consent, clinician credentials, work-up insistence, traceability — as non-negotiable, to read rules six through eleven as the structural texture against which institutional discipline becomes legible, and to weight rule twelve only after the structural rules have been read. A patient who arrives with the twelve rules internalised is in the consult conversation the conservative Korean practices most welcome; a patient who arrives with a louder framework — a ranking, a 'best-of' folder, a same-day-procedure expectation — is in a conversation the older clinicians treat with more reservation. The cleaner consults read calmly. The framework is meant to read calmly with them. The rules do not, and are not intended to, recommend a clinic. 慢慢諗清楚再做決定 — work it through, and then decide.

Frequently asked questions

Are the twelve rules ranked from most to least important?

No, and the editorial register is intentional. The rules are categorical rather than ranked, and the conservative reading is to treat rules one through five as non-negotiable, rules six through eleven as the structural texture against which institutional discipline becomes legible, and rule twelve as a tiebreaker only after the structural rules have been read. The framework is for the patient's consult conversations rather than a hierarchy of clinics, and no practice is named or positioned against another in the editorial register.

How can I verify a practice's MFDS cellular-therapy registration before I travel?

The Korean Ministry of Food and Drug Safety maintains a publicly accessible cellular-therapy register that lists currently registered protocols and their indication scopes. Patients can request the practice's registration reference at the inquiry stage and verify it directly against the public register before any consult fee is paid. The conservative practices treat the verification as routine; the practices that soften the question at the inquiry stage are signalling something a careful patient should attend to before the travel arc begins.

What does $, $$, and $$$ mean across the rules' pricing-tier columns?

The tiers are categorical reading frames rather than absolute price points. $ indicates a discipline whose presence does not meaningfully add to the headline procedure cost; $$ indicates a discipline that is structural and itemised in the practice's quotation; $$$ indicates a discipline whose institutional infrastructure — laboratory, surveillance, senior clinician fee, hospitality cadence — reads into the pricing floor. The tiers are intended as a reading frame rather than a price-quote register, and any actual pricing read should come from the practice's itemised quotation.

Can a newer practice satisfy the twelve rules?

Some rules — MFDS registration, advance consent delivery, itemised quotation, evidence-base verification — are achievable across both newer and longer-tenured practices, and a careful patient should not weight tenure exclusively. Other rules — pharmacovigilance discipline, redirection willingness, foreign-patient infrastructure depth, consult-room atmosphere — accumulate institutionally and read more reliably in the longer-tenured practices. The conservative reading is to weight the institutional rules more heavily for indications where the cellular protocol is more consequential.

Why are no specific clinics named or recommended?

Korean medical-tourism law (Article 56(4) of the Medical Service Act) treats direct ranking and named comparison of healthcare providers in foreign-patient contexts as a regulated matter, and the editorial register here is calibrated to the legal framework. The list is intentionally categorical — qualifications, facilities, regulatory registers, and consult-room disciplines — rather than directional. Patients should use the framework to evaluate practices in their own consult conversations rather than as a directory of recommended clinics.

How long should the full consult arc take if a practice satisfies these rules?

In the conservative Korean register, a serious cellular-therapy consult arc runs across multiple visits — an initial consult of forty-five to sixty minutes for the indication conversation, a separate work-up visit for imaging and laboratory work, and a returning consult for the protocol-and-consent conversation after the work-up has been read. A consult arc compressed into a single visit, with the cellular protocol named and scheduled in the same hour, is — measured against the rules above — running thinner than the cleaner practices sustain.

What if a practice satisfies eleven of the twelve rules but falls on one?

The reading depends on which rule. A practice that falls on one of the structural rules (cost transparency, foreign-patient infrastructure, atmosphere) may be readable as a corridor-quality practice with operational thinning that a patient could navigate with caution. A practice that falls on one of the non-negotiable rules (MFDS registration, advance consent, clinician credentials, work-up rigour, traceability) is, in the conservative reading, the practice to step back from regardless of how strongly the remaining rules read.

Do these rules apply equally to aesthetic and orthopaedic cellular protocols?

Yes, with calibration. The regulatory, credential, traceability, work-up, consent, pharmacovigilance, transparency, foreign-patient, evidence-base, and editorial-disposition rules all apply to aesthetic cellular protocols (skin substrate, dermal regeneration, hair-restoration) as straightforwardly as they do to orthopaedic and longevity-medicine cellular work. The indication-driven consult rule reads slightly differently in the aesthetic register — the work-up modalities differ — but the underlying discipline is identical.